The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 3.49 — safe zoneOK
- Earnings-manipulation signal · Beneish M -2.87 — no flag raisedOK
- Earnings quality 69/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as OCULAR THERAPEUTIX, INC reports it. History and quarterly detail are in the app.
- Product revenue, net$51.8M
- Collaboration revenue$128K
Leadership changes
From OCULAR THERAPEUTIX, INC's own filings, the day they're filed.
- Jason Robins · Chief Financial Officer · appointmenteff. 2026-06-10
- Jason Robins · Chief Financial Officer · appointmenteff. 2026-01-20
- Donald Notman · Chief Operating Officer · appointmenteff. 2024-08-29
Latest filings
- 8-K · Company announcement2026-08-03
- 10-Q · Quarterly report2026-08-03
- 8-K · Company announcement2026-06-12
- 10-Q · Quarterly report2026-05-05
- 8-K · Company announcement2026-05-05
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about OCULAR THERAPEUTIX, INC, every answer cited to the official filings🔒
- The Intelligence Brief — added when OCULAR THERAPEUTIX, INC's brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.